Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AFMD Affimed	$0.18 -34.9%	$0.25	$0.07 ▼ $5.48	$2.92M	2.07	4.87 million shs	22.99 million shs
LGVN Longeveron	$0.80 0.0%	$1.29	$0.63 ▼ $2.67	$12.14M	0.23	1.95 million shs	556,700 shs
SNPX Synaptogenix	$7.65 +18.6%	$7.19	$1.84 ▼ $7.85	$10.63M	1.08	250,819 shs	339,418 shs
TAOX Synaptogenix	$7.65 +18.6%	$0.00	$1.84 ▼ $11.98	$26.68M	1.87	287,574 shs	337,606 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AFMD Affimed	0.00%	0.00%	0.00%	0.00%	-95.74%
LGVN Longeveron	0.00%	+5.24%	-52.67%	-40.76%	-68.76%
SNPX Synaptogenix	+18.60%	-8.93%	-19.47%	+242.28%	+101.32%
TAOX Synaptogenix	0.00%	-8.93%	+764,999,900.00%	+764,999,900.00%	+764,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AFMD Affimed	1.8473 of 5 stars	3.0	0.0	0.0	4.3	0.0	0.0	1.3
LGVN Longeveron	3.4259 of 5 stars	3.5	5.0	0.0	0.0	1.7	1.7	1.3
SNPX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AFMD Affimed	2.00	Hold	$3.62	1,895.87% Upside
LGVN Longeveron	3.00	Buy	$7.25	806.48% Upside
SNPX Synaptogenix	0.00	N/A	N/A	N/A
TAOX Synaptogenix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AFMD, SNPX, TAOX, and LGVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/15/2025	LGVN Longeveron	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $3.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AFMD Affimed	$877K	3.33	N/A	N/A	$4.19 per share	0.04
LGVN Longeveron	$2.39M	5.08	N/A	N/A	$1.47 per share	0.54
SNPX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AFMD Affimed	-$114.66M	N/A	0.00	N/A	N/A	-7,836.26%	-193.84%	-107.24%	9/1/2025 (Estimated)
LGVN Longeveron	-$15.97M	-$6.28	0.00	N/A	N/A	-894.40%	-95.91%	-79.69%	11/11/2025 (Estimated)
SNPX Synaptogenix	-$12.77M	-$10.08	N/A	∞	N/A	N/A	-115.28%	-58.31%	N/A
TAOX Synaptogenix	-$12.77M	-$20.16	N/A	∞	N/A	N/A	-277.76%	-150.79%	N/A

Latest AFMD, SNPX, TAOX, and LGVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/15/2025	Q2 2025	TAOX Synaptogenix	N/A	-$11.26	N/A	-$11.26	N/A	N/A
8/13/2025	Q2 2025	LGVN Longeveron	-$0.35	-$0.33	+$0.02	-$0.33	$0.41 million	$0.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AFMD Affimed	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
SNPX Synaptogenix	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AFMD Affimed	0.13	1.93	1.93
LGVN Longeveron	N/A	3.43	3.43
SNPX Synaptogenix	N/A	72.59	72.59
TAOX Synaptogenix	N/A	20.52	20.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AFMD Affimed	30.82%
LGVN Longeveron	10.01%
SNPX Synaptogenix	10.34%
TAOX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
AFMD Affimed	3.80%
LGVN Longeveron	11.20%
SNPX Synaptogenix	2.73%
TAOX Synaptogenix	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AFMD Affimed	200	16.10 million	15.49 million	Optionable
LGVN Longeveron	20	15.18 million	13.48 million	Not Optionable
SNPX Synaptogenix	4	1.39 million	1.35 million	Not Optionable
TAOX Synaptogenix	4	3.49 million	3.39 million	N/A

AFMD, SNPX, TAOX, and LGVN Headlines

Recent News About These Companies

Wall Street Zen Downgrades Synaptogenix (NASDAQ:TAOX) to Sell

August 19, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AFMD, SNPX, TAOX, and LGVN Company Descriptions

Affimed NASDAQ:AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Longeveron NASDAQ:LGVN

$0.80 0.00 (-0.03%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.81 +0.01 (+1.28%)

As of 08/22/2025 07:51 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Synaptogenix NASDAQ:SNPX

$7.65 +1.20 (+18.60%)

As of 08/22/2025

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

Synaptogenix NASDAQ:TAOX

$7.65 +1.20 (+18.60%)

As of 08/22/2025 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time